Posted by THTX March is National Colorectal Cancer Awareness Month
It is the third most commonly diagnosed cancer in men and women combined and the second leading cause of cancer death in men and women combined in the U.S.
Theratechnologies is developing a new class of treatment targeting all SORT1+ #cancers by linking approved anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. The expression of the sortilin receptor has been documented in multiple cancers, including ovarian, endometrial, triple negative breast, melanoma, lung, #colorectal and pancreatic cancers, among others. https://lnkd.in/eK7x2Rer
https://www.linkedin.com/posts/theratechnologies-inc_cancers-colorectal-activity-6904395153025359872-SqiE